Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BNT141 |
Synonyms | |
Therapy Description |
BNT141 consists of an mRNA encoding an anti-CLDN18.2 monoclonal antibody contained within a lipid nanoparticle, which may lead to inhibition of tumor-expressed CLDN18.2, potentially resulting in tumor cell death (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BNT141 | BNT-141|BNT 141 | BNT141 consists of an mRNA encoding an anti-CLDN18.2 monoclonal antibody contained within a lipid nanoparticle, which may lead to inhibition of tumor-expressed CLDN18.2, potentially resulting in tumor cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04683939 | Phase Ib/II | BNT141 BNT141 + Gemcitabine + Nab-paclitaxel | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | Terminated | USA | CAN | 0 |